Affordable Access

Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis.

Authors
  • Hayashi, Tatsuyuki
  • Yamaguchi, Izumi
  • Saitoh, Hiroki
  • Takagi, Masao
  • Nonaka, Yasunobu
  • Nomura, Takeo
Type
Published Article
Journal
Internal medicine (Tokyo, Japan)
Publication Date
Jul 01, 2003
Volume
42
Issue
7
Pages
605–608
Identifiers
PMID: 12879955
Source
Medline
License
Unknown

Abstract

A 64-year-old Japanese man suffering from IgD lambda myeloma and renal failure requiring chronic hemodialysis was treated with thalidomide. Serum IgD concentration was 4,050 mg/dl and myeloma cells constituted 95.6% of nucleated cells in bone marrow at the start of treatment. These parameters improved markedly to 1,590 mg/dl and 22.0%, respectively, in the 4 months immediately prior to his death due to pneumonia. Thalidomide caused peripheral neuropathy and constipation at a dose of 100 mg daily in the first week of treatment, but adverse effects resolved upon dose reduction. Thalidomide represents a valid therapeutic option for some myeloma patients receiving hemodialysis.

Report this publication

Statistics

Seen <100 times